Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Bausch (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Bausch (BHC) Might Surprise This Earnings Season

LAVAL, Quebec, Aug. 2, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that it and certain of its affiliates have completed the previously announced sale of all of their equity interests in Amoun Pharmaceutical Company S.A.E. ("Amoun") to Abu-Dhabi based ADQ, one of the region's largest holding companies, for total gross consideration of approximately U.S. $740 million, subject to certain adjustments.1 "With the closing of the Amoun deal, we will be able to further reduce overall Bausch Health debt," said Joseph C.

Bausch Health Completes Sale Of Amoun Pharmaceutical To ADQ

Ironwood Pharma

Regeneron Pharmaceuticals

Zoetis

We take a look at a few pharma/biotech companies, which are poised to beat on earnings in the second quarter.

4 Pharma/Biotech Stocks Poised to Beat on Earnings in Q2

Scholarships Awarded to Nine Students Affected by Dermatologic Conditions LAVAL, Quebec, July 29, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the recipients of their 2021 Aspire Higher scholarship program. The program, which began in 2012, will award nine students who have been treated for a dermatologic condition with a scholarship of up to $10,000 to pursue their undergraduate or graduate degrees.

Ortho Dermatologics Announces 2021 Aspire Higher Scholarship Recipients

Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Bausch (BHC) is Poised to Beat Earnings Estimates Again

LAVAL, Quebec, July 22, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) diseases, today announced the winners of its 2021 Salix Gastrointestinal Health Scholars Program. Ten students living with a GI disease will each receive a $10,000 scholarship; a total of $100,000 in scholarships was awarded.

Salix Announces 2021 Gastrointestinal Health Scholars Program Winners

LAVAL, Quebec, July 19, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the presentation of 14 scientific posters involving the company's ophthalmic surgical technologies at the American Society of Cataract and Refractive Surgery annual meeting, which will take place from July 23-27, 2021, in Las Vegas. "Bausch + Lomb is committed to supporting continued research on our eye health products, because we recognize this is essential to fostering the kind of peer-to-peer discussion and learning that ultimately helps promote better patient outcomes," said Joe Gordon, U.S. president, Bausch + Lomb.

Bausch + Lomb Will Present 14 Scientific Posters Featuring New Analyses Involving Its Surgical Technologies At The 2021 Annual Meeting Of The American Society Of Cataract And Refractive Surgery

New Preservative-Free and pH-Balanced Products Formulated for Irritated, Dry Eyes Now Rolling out to Major U.S. Retailers LAVAL, Quebec, July 12, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the U.S. launch of Biotrue® Hydration Boost Lubricant Eye Drops and Biotrue® Micellar Eyelid Cleansing Wipes. Both products are preservative-free and uniquely formulated with naturally inspired ingredients to relieve symptoms associated with irritated, dry eyes.

Bausch + Lomb Launches Biotrue® Hydration Boost Lubricant Eye Drops and Biotrue® Micellar Eyelid Cleansing Wipes

LAVAL, QC and HEIDELBERG, Germany, July 7, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced the second of two Phase 3 (MOJAVE) studies evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD), has been completely enrolled with a total of 622 participants. Dry eye disease, one of the most common ocular surface disorders, causes discomfort for millions of Americans, and MGD plays a key role in the development of this disease.1,2  "With its novel mechanism of action, NOV03, if approved, may be a first-in-class treatment option to specifically treat the symptoms of dry eye disease associated with MGD," said Joseph C.

Bausch + Lomb Completes Enrollment Of Second Phase 3 Study For NOV03 (perfluorohexyloctane)

LAVAL, QC, July 6, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its second-quarter 2021 financial results on Tuesday, Aug. 3, 2021. Bausch Health will host a conference call and live web cast at 8:00 a.m.

Bausch Health Companies Inc. Will Release Second-Quarter 2021 Financial Results On August 3

Bausch Health Industries Inc. said Thursday it is reducing its debt by $150 million through the redemption of outstanding bonds using cash from operations. The company, the former Valeant, has regularly made such moves as it works to reduce a debt burden that stood at $23.7 billion at the end of March, according to FactSet data.

Bausch Health reduces debt by $150 million by redeeming bonds

LAVAL, Quebec, July 1, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it will reduce debt by $150 million through the redemption of outstanding senior notes, using cash generated from operations. Bausch Health will redeem $150 million aggregate principal amount of its outstanding 6.125% Senior Notes due 2025, CUSIP Nos.

Bausch Health To Reduce Debt By $150 Million Using Cash Generated From Operations

Nicox's Licensee Bausch + Lomb Receives Approval for VYZULTA®

Nicox's Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates

New Parameters Provide a Broader Offering for Presbyopic Patients with Astigmatism LAVAL, QB, June 23, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the U.S.  launch of expanded parameters for Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses. The expansion, which includes the addition of -2.25D and -2.75D cylinder power parameters, will be part of the company's standard offering of the lens and will extend the power range available to eye care professionals and their patients who have both astigmatism and presbyopia.

Bausch + Lomb Expands Parameters for Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses

LAVAL, QC, June 22, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC)("Bausch Health," the "Company" or the "Offeror") today announced that it has extended the expiration date for its previously announced cash tender offer (the "Tender Offer") to purchase any and all of its outstanding 7.00% Senior Secured Notes due 2024 (the "Notes"). The Offeror's obligation to accept and pay for the Notes remains subject to the terms of the Tender Offer as described in the Offer to Purchase, dated May 24, 2021 (the "Offer to Purchase").

Bausch Health Announces Extension Of Its Tender Offer For Cash Tender Offer For Senior Secured Notes By One Business Day To Reflect The Federal Holiday On June 18, 2021

LAVAL, QC, June 21, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that D. Robert Hale has resigned from his role as an independent director of the Company's Board of Directors ("Board") to focus on other business obligations related to his firm, ValueAct Capital ("ValueAct"), a shareholder of the Company.

Bausch Health Announces D. Robert Hale Has Resigned From Its Board Of Directors

LAVAL, QB and ST. PAUL, Minn., June 8, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that its affiliate has entered into an agreement with Lochan LLC ("Lochan") to develop the next-generation of Bausch + Lomb's eyeTELLIGENCE™ clinical decision support software. Using the existing cloud-based infrastructure of eyeTELLIGENCE, this analytical software is being designed to allow surgeons to seamlessly integrate all aspects of the cataract, retinal and refractive surgery processes to maximize their overall practice efficiency. The companies expect to launch the initial phase of this next-generation software in 2022.

Bausch + Lomb and Lochan Enter Into Agreement to Develop the Next-Generation of eyeTELLIGENCE™ Clinical Decision Support Software

LAVAL, Quebec, June 7, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health," the "Company" or the "Offeror") announced today the results to date of its pending cash tender offer (the "Tender Oﬀer"), to purchase any and all of its outstanding 7.00% Senior Secured Notes due 2024 (the "Notes"), as well as the anticipated early settlement date for the Tender Offer on June 8, 2021 (the "Early Settlement Date"). The terms and conditions of the Tender Offer are described in an Oﬀer to Purchase dated May 24, 2021 (as it may be amended or supplemented from time to time, the "Offer to Purchase").

Bausch Health Announces Early Tender Results And Early Settlement Date For Cash Tender Offer For Senior Secured Notes

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

Why Is Bausch (BHC) Up 13.8% Since Last Earnings Report?

Bumble

Beyond Meat

Looking for huge winners over the long run? Here are three top picks.

The 3 Best Stocks to Buy for Summer 2021

Bausch Health Companies Inc. (BHC) CEO Joseph Papa Presents at Jefferies Healthcare Conference Call Transcript

Clearside Biomedical

PDUFA Action Date Is October 30 , 2021 LAVAL, QC and ALPHARETTA, Ga., June 2, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, along with Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside"), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted New Drug Application for XIPERE™1 (triamcinolone acetonide suprachoroidal injectable suspension).

Bausch Health And Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension)

Organizations Also Launch Social Media Donation Program to Support Prevent Blindness and Broaden Patients' Access to Cataract Surgery and Care During June's Cataract Awareness Month LAVAL, QC and CHICAGO, June 1, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), and Prevent Blindness, the nation's oldest volunteer eye health non-profit organization, today announced that they are joining forces during Cataract Awareness Month in June to educate the public and raise awareness of the symptoms, causes and treatment options for cataracts, the leading cause of vision loss in the United States and the leading cause of blindness worldwide.1 Treatment options include cataract surgery, which is one of the most effective and common medical procedures with an overall success rate of 99 percent when performed in appropriate settings.2 Approximately four million cataract surgeries are performed each year in the United States.3 However, anxiety around the operation itself is experienced by many cataract surgery patients leading up to the procedure.4 "As a leader in eye health, Bausch + Lomb is proud to raise awareness of this incredibly common eye condition and its treatment options, particularly following the interruptions seen in routine medical healthcare as a result of the pandemic," said Joe Gordon, U.S. president, Bausch + Lomb. "We share this commitment with Prevent Blindness, an incredible organization that goes to extreme lengths to help people, and we look forward to working with them to provide people affected by cataracts with information and resources to support their care.

Bausch + Lomb and Prevent Blindness Launch Educational Campaign During Cataract Awareness Month

LAVAL, Quebec, May 27, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it will reduce debt by $100 million through the redemption of outstanding senior notes, using cash generated from operations. Bausch Health will redeem $100 million aggregate principal amount of its outstanding 6.125% Senior Notes due 2025, CUSIP Nos.

Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations

Bausch Health Companies Inc. (BHC) Management Presents at Barclays High Yield Bond Conference (Transcript)

News for Bausch Health Companies Inc Stock (BHC)